100% Same
Salt CompositionEffectivenessStrength
with Substitute Medicine
Salt Composition in bothYou Searched
Lapahope 250mg Tablet 120s
Glenmark Pharmaceuticals Ltd.
₹26,000
Our Recommendation
Lapahope 250mg Tablet 30s
392+ trust this
WHO GMP Certified
WHO GMP
Certified
15 Days Easy
Returns
Long Expiry
(>8 Months)
WHO GMP
Certified
15 Days Easy
Returns
Long Expiry
(>8 Months)
Delivery by
Used In
Breast cancer
Customers also bought
More About Lapahope
Benefits
In Breast cancer Lapahope 250mg Tablet helps to treat breast cancer and it may be used alone or in combination with other medicines or treatment modalities like chemotherapy. It relieves the symptoms of breast cancer such as breast lumps, bloody discharge from nipples or changes in the shape or texture of the breast. Lapahope 250mg Tablet kills or stops the growth of cancer cells and also prevents the multiplication of cancer cells. Discuss with your doctor if any of the side effects bother you.
Side Effects
The majority of side effects typically do not necessitate medical intervention. and disappear as your body adjusts to the medicine. Doctor consultation is advised if they persist or if you're worried about them.
How to use
Follow your doctor's guidance regarding the dose and duration of this medication. Ingest it without breaking or crushing. Do not chew, crush or break it. Lapahope 250mg Tablet is to be taken empty stomach.
How it works
Lapahope 250mg Tablet is an anti-cancer medication. It works against the HER2 (human epidermal growth factor receptor protein) receptors and EGFRs (epidermal growth factor receptor) which are responsible for the over-proliferation of cells. This is how it inhibits the growth of cancerous cells causing downstream signaling pathways.
Consult your Doctor: Please consult your doctor regarding the safety of consuming alcohol with Lapahope 250mg Tablet 120 Tablet . Experts have not found evidence of alcohol impairing the effectiveness of the medicine.
Seek medical advice from your doctor: Lapahope 250mg Tablet is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Doctor consultation is advised.
Not Safe: Lapahope 250mg Tablet is unsafe to use during breastfeeding. Data suggests that the drug may cause toxicity to the baby.
Not Safe: Lapahope 250mg Tablet may cause side effects which could affect your ability to drive.
Caution Advised: Lapahope 250mg Tablet should be used with caution in patients with severe kidney disease. Dose adjustment of Lapahope 250mg Tablet may be needed. Doctor consultation is advised. Limited information is available on the use of Lapahope 250mg Tablet in these patients. No dose adjustment is recommended in patients with mild to moderate kidney disease.
Caution Advised: Lapahope 250mg Tablet should be used with caution in patients with liver disease. Dose adjustment of Lapahope 250mg Tablet may be needed. Doctor consultation is advised. Limited information is available on the use of this medicine in patients with the severe liver disease.
What if I forget to take it?
If a dose of Lapahope 250mg Tablet 120 Tablet is missed, it's advisable to consult your doctor.
Manufacturer Address
Glenmark Pharmaceuticals Limited, B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai 400 026.
References
Chabner BA, Barnes J, Neal J, et al. Targeted Therapies: Tyrosine Kinase Inhibitors, Monoclonal Antibodies, and Cytokines. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilmans: The Pharmacological Basis of Therapeutics. 12th ed. New York, New York: McGraw-Hill Medical; 2011. pp. 1737-38
Briggs GG, Freeman RK, editors. A Reference Guide to Fetal and Neonatal Risk: Drugs in Pregnancy and Lactation. 10th ed. Philadelphia, PA: Wolters Kluwer Health; 2015. pp. 779-80
Lapatinib ditosylate monohydrate. Camberley, Surrey: Novartis Pharmaceuticals UK Ltd.; 2008 (23 Jan. 2019)
Lapatinib. Research Triangle Park, North Carolina: GlaxoSmithKline; 2007 (26 Mar. 2019)
Drugs and Lactation Database (LactMed) (18 Feb. 2020)
Central Drugs Standard Control Organisation (CDSCO) (26 Mar. 2019)
Disclaimer
PlatinumRx is dedicated to delivering dependable and trustworthy information to empower our customers. However, the information presented here is solely for general informational purposes and should not be utilized for diagnosing, preventing, or treating health issues. It is not intended to establish a doctor-patient relationship or serve as a substitute for professional medical advice.
